DMD WarrioR

SonoThera’s RIPPLE Technology Offers Hope for Full-Length Human Dystrophin 👉 Read More: DMDWarrioR.com

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing #saRNA Therapeutic for #Duchenne Muscular Dystrophy 👉 Read More: DMDWarrioR.com

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy 👉 Read More: DMDWarrioR.com

Satellos reported that the FDA and other global regulators have cleared its IND for SAT-3247, enabling a three-month Phase 2, placebo-controlled trial in 51 ambulatory children with Duchenne muscular dystrophy. #satellos #dmd #duchenne 👉 Read More: DMDWarrioR.com

Researchers Buel D. Rodgers and Christopher W. Ward published a groundbreaking study in Gene Therapy that unveiled a codon-optimized human Smad7 gene therapy aimed at treating Duchenne muscular dystrophy (DMD). 👉 Read More: DMDWarrioR.com

ELEVIDYS Gene Therapy for Non-Ambulant Children with DMD: FDA OKs ENDEAVOR Cohort 8 Immunosuppression Study 👉 Read More: DMDWarrioR.com

Potential of SAT-3247 to Restore Muscle Regeneration in Duchenne Published in Nature 👉 Read More: DMDWarrioR.com

DMD ANKA mRNA therapy, currently under development for Duchenne muscular dystrophy in Turkiye, was announced by Associate Professor Dr. Ali Taghizadeh. 👉 Read More: DMDWarrioR.com

REGENXBIO Announces Completion of RGX-202 Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program #dmd #duchenne #regenxbio #genetherapy #clinicaltrials #rgx202 👉 Read More: DMDWarrioR.com

Hansa’ Imlifidase Reduce Anti-AAV Antibodies and Allow Administration of Gene Therapy #dmd #duchenne #imlifidase #genetherapy #clinicaltrials 👉 Read More: DMDWarrioR.com

Why Elevidys Was Not Approved by the European Medicines Agency (EMA)? You can access the comprehensive report on the reasons for the Elevidys refusal published by EMA from our web page link. #dmd #duchenne #elevidys #eu 👉 Read More: DMDWarrioR.com

Brogidirsen (NS-089/NCNP-02) has The Potential to Slow Disease Progression in DMD Patients Amenable to Exon 44 Skipping #dmd #duchenne #exon44 #brogidirsen 👉 Read More: DMDWarrioR.com

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 #dmd #duchenne #delzota #exon44 #exon44skipping #clinicaltrials #aviditybiosciences 👉 Read More: DMDWarrioR.com

Does Pulsed Electromagnetic Field (PEMF) Therapy Treat Duchenne Muscular Dystrophy and Initiate Dystrophin Production? #pemf #dmd #duchenne 👉 Read More: DMDWarrioR.com

Tevard Biosciences Presents Data Demonstrating Production of Full-Length Protein with tRNA-Based Therapy for Duchenne Muscular Dystrophy #dmd #duchenne

Cures of #Duchenne (Detailed List of All Clinical Trials for #DMD) List of all researches such as #gene therapy, exon skipping, reducing inflammation and improving #muscle growth & protection cures for duchenne #muscular dystrophy. dmdwarrior.com/dmd-treatmen...

Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial #dmd #duchenne #delzota #exon44 #exon44skipping #clinicaltrials #aviditybiosciences 👉 Read More: DMDWarrioR.com

Belief BioMed Announced Successful Completion of First Dose of BBM-D101 Gene Therapy #dmd #duchenne #BBMD101 #BeliefBioMed #clinicaltrials 👉 Read More: DMDWarrioR.com

Solid Biosciences Initiates Phase 3 Clinical Trial of SGT-003 Gene Therapy (IMPACT DUCHENNE) in Ambulant Males #dmd #duchenne #sgt003 #genetherapy #clinicaltrials 👉 Read More: DMDWarrioR.com

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting #dmd #duchenne #ker065 👉 Read More: DMDWarrioR.com

GNR-097: Duchenne Gene Therapy Phase 1/2 Study Started by Generium Generium is a Russian innovative biotechnology company has received approval to conduct a clinical trial of GNR-097 gene therapy drug for the treatment of progressive Duchenne muscular dystrophy (DMD). 👉 Read More: DMDWarrioR.com

🎈 SEPTEMBER 7, 2025 🎈 Support World Duchenne Awareness Day 2025 with DMDWarrior Theme of 2025: Make Cures Affordable for Duchenne #WorldDuchenneAwarenessDay #dmdwarrior #SupportDuchenne #DMD #WDAD #UntilEveryoneHasACure #TogetherWeThrive #Becker #MuscularDystrophy #ExonSkipping

How Does My Child Participate in Clinical Trials for Duchenne? Learn how your child can join Duchenne muscular dystrophy (DMD) clinical trials and discover trusted resources to find active studies near you. Learn More 👇 dmdwarrior.com/how-to-parti...

🎈 SEPTEMBER 7, 2025 🎈 Support World Duchenne Awareness Day 2025 with DMDWarrior Theme of 2025: Make Cures Affordable for Duchenne #WorldDuchenneAwarenessDay #dmdwarrior #SupportDuchenne #DMD #WDAD #UntilEveryoneHasACure #TogetherWeThrive #Becker #MuscularDystrophy #ExonSkipping

ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy #givinostat #duvyzat 👉 Read More: DMDWarrioR.com

Agamree to be sold in United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain starting in 2026 #agamree #vamorolone #uae #bahrain #oman #saudi_arabia #kuwait 👉 Read More: DMDWarrioR.com

FDA: ‘Elevidys Gene Therapy Will Continue to Be Used in Ambulatory DMD Patients’ #dmd #sarepta #roche #elevidys #fda #duchenne 👉 Read More: DMDWarrioR.com

FDA Investigating Death of 8-Year-Old Brazilian Boy Who Received Elevidys #dmd #sarepta #roche #elevidys #fda #duchenne 👉 Read More: DMDWarrioR.com

The European Medicines Agency (EMA) Issued a Negative Opinion on Elevidys #dmd #sarepta #roche #elevidys #europe #ema 👉 Read More: DMDWarrioR.com

Roche Suspends Shipments of Elevidys Gene Therapy Outside of the United States #dmd #sarepta #roche #elevidys 👉 Read More: DMDWarrioR.com

Sarepta Reported Elevidys Gene Therapy for Duchenne Muscular Dystrophy will not be used in non-ambulatory patients. #dmd #sarepta #roche #elevidys 👉 Read More: DMDWarrioR.com

Entrada Therapeutics Receives EU Authorization to Start Exon 45 Skipping Clinical Trial in Duchenne Muscular Dystrophy #dmd #duchenne 👉 Read More: DMDWarrior.com

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy 👉 DMDWarrioR.com #dmd #duchenne #deramiocel #cardiomiopathy

Tevard Biosciences to Present Data Demonstrating tRNA-based Therapy Rescued Full-Length Dystrophin and Motor Function in Duchenne Muscular Dystrophy Model 👉 DMDWarrioR.com #dmd #duchenne #tRNA #Dystrophin

EMA Recommends EU Approval for Duvyzat (givinostat) to Treat Duchenne Muscular Dystrophy #dmd #duchenne #ema #duvyzat #givinostat 👉 DMDWarrioR.com

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy #dmd #duchenne #dyne #dyne-251 #exon51 #exon51skipping #exonskipping #ema #orphandrug

Agamree (vamorolone) will be Covered in Slovenia by the Slovenian Health Insurance Fund The drug will be covered by the Slovenian Health Insurance Fund as of April 23, 2025. #dmd #duchenne #agamree #vamorolone #Slovenia

Russia-Based Circle of Kindness Foundation Announces 18% Price Cut for Elevidys Gene Therapy #dmd #elevidys #russia #duchenne #dmdwarrior 👉 Read More: DMDWarrioR.com

mRNA Studies in DMD Treatment: Future Therapeutic Candidates Duchenne Muscular Dystrophy (DMD) mRNA Studies May Provide Full-Length and Normal Dystrophin Production. #dmd #mrna #duchenne #dmdwarrior 👉 Read More: DMDWarrioR.com

Three Ongoing Clinical Trials of Elevidys Gene Therapy Temporarily Halted in Europe Why Were Elevidys Clinical Trials Halted? 👉 DMDwarrior.com

GenAssist Announces FDA Approval of New Drug Application for GEN6050X Exon 50 Skipping Therapy 👉 Read More: dmdwarrior.com #dmd #duchenne #GenAssist #GEN6050X #exon50 #exon50skipping

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy 👉 Read More: dmdwarrior.com #dmd #duchenne #deramiocel #capricor

Entrada Therapeutics Receives FDA Approval to Begin Clinical Trial of ENTR-601-44 Exon Skipping Treatment 👉 Read More: dmdwarrior.com #dmd #duchenne #exon44 #exon44skipping #exonskipping

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 👉 Read More: dmdwarrior.com #dmd #duchenne #solidbio #sgt-003 #genetherapy

We Call on Health Ministries and Pharmaceutical Manufacturers to Take Action on Duchenne Treatments Who is Guilty? 👉 Read More: dmdwarrior.com #dmd #dmdwarrior #duchenne @fda.gov @ema.europa.eu @ec.europa.eu @who.int @anvisaoficial.bsky.social

Duchenne Muscular Dystrophy Market Grows: But Not All Families Have Access to Treatments 👉 Read More: dmdwarrior.com #dmd #dmdwarrior #duchenne

Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany 👉 Read More: dmdwarrior.com

The Challenge of Getting DMD Gene Therapy: Is Geography Destiny? #duchenne #dmd #duchennemusculardystrophy #dmdwarrior #duchenneawareness 👉 Read More: dmdwarrior.com

Satellos Announces Completed Enrollment of Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers #duchenne #dmd #duchennemusculardystrophy #dmdwarrior #duchenneawareness #satellos 👉 Read More: dmdwarrior.com

Cumberland Pharmaceuticals Announces Fantastic Results from Phase 2 FIGHT Duchenne Trial in DMD Heart Disease What is Ifetroban? 👉 Read More: dmdwarrior.com